What Seagen does

Seagen is an oncology-focused biotechnology company specializing in antibody-drug conjugate (ADC) technology for the targeted treatment of solid tumor cancers. Founded in 1997 and headquartered in Bothell, Washington, Seagen developed ADCs that use monoclonal antibodies conjugated to cytotoxic agents via proprietary linker chemistries, enabling selective delivery of cell-killing payloads to cancer cells expressing specific antigens while limiting damage to healthy tissue. Its commercial portfolio comprises PADCEV (enfortumab vedotin) for urothelial carcinoma, co-developed with Astellas Pharma; TIVDAK (tisotumab vedotin) for recurrent or metastatic cervical cancer, co-commercialized with Genmab in the United States and licensed to Zai Lab for Greater China; and Tukysa (tucatinib), an oral HER2 inhibitor for HER2-positive metastatic breast cancer. The ADC platform architecture is the central technical asset, supported by an extensive patent estate covering antibody engineering, linker chemistry, and payload delivery, and by a pipeline that previously included sigvotatug vedotin (integrin beta-6-targeted ADC for lung cancer, which failed Phase 3 in June 2026) and disitamab vedotin (discontinued in February 2026).

Seagen was acquired by Pfizer in late 2023 for approximately $43 billion, one of the largest oncology-focused pharmaceutical transactions on record, and now operates as a wholly-owned subsidiary with its Bothell R&D facility retained. Revenue is generated primarily through prescription-based sales of marketed ADCs to hospitals, oncology centers, and specialty pharmacies globally, distributed through Pfizer's commercial infrastructure. A secondary revenue stream comes from licensing and royalty arrangements, including the Zai Lab exclusive license for TIVDAK in Greater China and the Genmab co-commercialization arrangement in the United States. According to Pfizer CEO Albert Bourla at the 2026 AGM, the acquired Seagen portfolio delivered $10.2 billion in full-year revenue. Pfizer has positioned the ADC franchise as central to its post-COVID oncology growth strategy, aiming to offset upcoming patent cliffs on legacy blockbusters.

Name

Seagen

Legal name

Seagen Inc.

Website

https://seagen.com

Company type

Private

Founded year

1997

Operating status

Acquired

Headcount range

1,001–5,000 employees

Short description

Seagen is an oncology-focused biotechnology company that develops antibody-drug conjugate (ADC) therapies for solid tumor cancers, including PADCEV for bladder cancer, TIVDAK for cervical cancer, and Tukysa for HER2-positive breast cancer. Acquired by Pfizer in late 2023 for approximately $43 billion, it now operates as a wholly-owned subsidiary distributed through Pfizer's global pharmaceutical infrastructure.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

Keywords

• Antibody-drug conjugates
• Oncology therapeutics
• Targeted cancer therapy
• ADC technology platform
• Biopharmaceutical drugs

Headquarters

HQ city

Bothell

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations

Revenue model

1. Pharmaceutical Drug Sales: Revenue generated from the sale of marketed ADC cancer therapies including TIVDAK, PADCEV (enfortumab vedotin), and Tukysa (tucatinib). These are distributed through prescription-based model to healthcare providers and hospitals.
2. Licensing and Royalty Revenue: Seagen (now Pfizer) generates licensing revenue through partnerships such as the exclusive license agreement with Zai Lab for TIVDAK in Greater China, and co-commercialization arrangements with Genmab for Tivdak in the United States.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Seagen is a biotechnology company that develops and commercializes antibody-drug conjugate (ADC) therapeutics for solid tumor cancers. Its commercial portfolio includes PADCEV for urothelial (bladder) cancer, TIVDAK for recurrent/metastatic cervical cancer, and Tukysa for HER2-positive metastatic breast cancer. The company's ADC platform enables targeted delivery of cytotoxic agents directly to cancer cells while sparing healthy tissue.

Product overview

Seagen (acquired by Pfizer for $43 billion in late 2023) was an oncology-focused biopharmaceutical company specializing in antibody-drug conjugate (ADC) technology. Its commercial portfolio included PADCEV for bladder cancer (co-developed with Astellas), TIVDAK for cervical cancer (co-commercialized with Genmab), and Tukysa for HER2-positive breast cancer. The ADC technology platform uses targeted delivery of cytotoxic agents via monoclonal antibodies to tumor cells expressing specific antigens. Pipeline assets included sigvotatug vedotin (lung cancer, failed Phase 3 in 2026) and disitamab vedotin (discontinued in 2026). The ADC portfolio was central to Pfizer's oncology growth strategy.

Differentiator

Problem solved

Functional benefit

Brands

• ADC Technology Platform: Antibody-drug conjugate technology platform for targeted cancer therapeutics
• PADCEV
• Tukysa
• TIVDAK

Products and services

• PADCEV (enfortumab vedotin) An FDA-approved ADC targeting Nectin-4 for adults with locally advanced or metastatic urothelial (bladder) cancer. Co-developed with Astellas Pharma; FDA-approved in combination with pembrolizumab (Keytruda) for muscle-invasive bladder cancer.
• TIVDAK (tisotumab vedotin) A tissue factor-directed ADC for adult patients with recurrent or metastatic cervical cancer who have progressed on or after chemotherapy. Co-commercialized with Genmab in the United States; first ADC approved for cervical cancer in China.
• Tukysa (tucatinib) An oral small-molecule HER2 inhibitor for HER2-positive metastatic breast cancer, used in combination with trastuzumab and pertuzumab. Being evaluated for first-line maintenance therapy in the metastatic setting.
• Sigvotatug vedotin An ADC targeting integrin beta-6 protein expressed in approximately 90% of non-small cell lung cancers. Acquired through Pfizer's Seagen acquisition; Phase 3 SigVie-002 trial did not meet primary endpoint of overall survival benefit.

Quantifiable outcome

• TIVDAK demonstrated 45% reduction in risk of death vs chemotherapy in China subpopulation Phase 3 innovaTV 301 trial
• +1 more outcomes

Named customers2 records

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• GenmabcoreStrategic or Co-development Partner · 1 April 2024Genmab co-commercializes Tivdak with Seagen in the United States for cervical cancer treatment. This partnership generates royalty and milestone income for the combined entity, with Genmab reporting continued royalty income from partnered oncology products.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• ImmunoGen: ImmunoGen is a pure-play ADC company (now an AbbVie subsidiary) that developed and commercializes ELAHERE (mirvetuximab soravtansine) for ovarian cancer. It competes with Seagen/Pfizer in the broader ADC landscape and represents a comparable ADC platform play acquired by a large pharma for similar strategic reasons.
• Genmab: Genmab co-develops and co-commercializes TIVDAK with Seagen/Pfizer in the United States and retains royalty/milestone rights on partnered oncology products. It is also an ADC developer in its own right, with multiple wholly-owned ADC programs, making it both a commercial partner and a direct competitive peer in the ADC space.
• Daiichi Sankyo: Daiichi Sankyo is the most direct ADC competitor, co-developing and commercializing Enhertu and datopotamab deruxtecan with AstraZeneca across HER2 and TROP2 targets. The two companies are locked in active patent litigation and compete head-to-head across multiple oncology indications where Seagen markets PADCEV, TIVDAK, and Tukysa.
• Astellas Pharma: Astellas is Seagen's co-development and co-commercialization partner for PADCEV (enfortumab vedotin) in bladder cancer, sharing development costs, milestones, and profits. As an established Japanese pharma with a dedicated oncology franchise, Astellas is both a partner and a peer with overlapping ADC interest and capability.

Emerging players

• Mersana Therapeutics: Mersana is a clinical-stage ADC company with a differentiated payload/linker platform (Dolasynthen, Immunosynthen) targeting solid tumors. As an emerging pure-play ADC developer, it overlaps with Seagen's technology category and competes for the same oncology development talent, partnerships, and commercial pathways.

Broad incumbents

• AstraZeneca: AstraZeneca is a broad oncology incumbent and Daiichi Sankyo's partner for Enhertu and datopotamab deruxtecan, directly competing with Seagen's ADC franchise in HER2-positive breast, lung, and other tumors. Its large oncology commercial footprint and combination strategies with Imfinzi/Imjudo make it a critical strategic competitor to the Seagen/Pfizer ADC portfolio.
• Gilead Sciences: Gilead's Kite Pharma and Trodelvy (an ADC for triple-negative breast cancer) make it a direct competitor in the ADC oncology space. As a top-tier biopharma with established global commercial infrastructure, Gilead competes with Seagen/Pfizer for hospital and oncology center share in breast and other solid tumors.
• Takeda Pharmaceutical: Takeda is a global oncology and specialty pharma incumbent with a heritage ADC collaboration history with Seagen and broad solid-tumor and hematology franchises. It competes for the same hospital/oncology prescribing share and partnership opportunities in the ADC and broader oncology markets.
• Bristol-Myers Squibb: BMS is a major oncology incumbent with broad chemotherapy, immunotherapy (Opdivo), and ADC-adjacent capabilities that compete with Seagen's solid-tumor franchises. It also represents a potential acquirer/partner for ADC assets and competes for share of voice with oncologists across bladder, breast, and lung indications.

Regional players

• Zai Lab: Zai Lab holds the exclusive license for TIVDAK in Greater China and commercializes it through its established China oncology infrastructure. While a partner rather than a competitor, Zai Lab is a regional biopharma player with its own ADC and oncology pipeline that competes for the same China oncology prescriber base.

Market position

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/SeagenGlobal
• LinkedInlinkedin.com/company/seagen

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds7 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Seagen